May 2011

MaRS Innovation, GlaxoSmithKline partner to accelerate translational research

Tuesday, May 31, 2011

MaRS Innovation (MI) and GlaxoSmithKline (GSK) have announced a new development fund—the GSK-MaRS Innovation Fund—to support and fast-track the commercialization of some of Canada’s most promising translational research coming from 16 leading academic health sciences centers, hospitals and universities derived from the MI membership.

[Read More]

NIHR Clinical Research Network studies hit record high

Tuesday, May 31, 2011

The number of commercial studies adopted into the National Institute for Health Research’s Clinical Research Network (NIHR CRN) Portfolio in England during the third quarter of 2010-2011 reached 115, the highest level since the network started compiling quarterly reports in 2008, according to PharmaTimes.

[Read More]

North American pharma growing by overseas acquisitions

Tuesday, May 31, 2011

European drugmakers have more competition for nearby buyouts these days, according to a report on FiercePharma. With North America’s pharma companies turning to international markets for growth, they’re scouting Central Europe, Eastern Europe, Turkey and the Middle East for potential generics deals, which is likely to push prices upward, experts told Dow Jones.

[Read More]

Bayer to cut 540 jobs

Friday, May 27, 2011

Bayer HealthCare is ending production of its multiple sclerosis drug Betaseron in Emeryville, Calif. and taking it to Germany, according to Fierce Pharma. The production move will cut about 540 jobs.  Betaseron will be produced under a contract with Boehringer Ingelheim.

[Read More]

Otonomy appoints Gerald Wroblewski as COO

Friday, May 27, 2011

Otonomy, a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, has appointed Gerald Wroblewski as the company’s chief operations officer.  The company has plans to initiate a phase II study for its lead drug candidate, OTO-104, in patients with Meniere’s disease and is also positioned to begin clinical trials of a second product candidate, OTO-201, by the end of 2011.

[Read More]

PharmaNet Canada to partner with HMR

Friday, May 27, 2011

PharmaNet Development Group, a provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced that its subsidiary, PharmaNet Canada, and Maisonneuve-Rosemont  Hospital (HMR) and its research center, will collaborate to conduct pharmacokinetic studies in patients with impaired renal function.

[Read More]